{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:39:00Z","timestamp":1793421540931,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd011346","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,2,8]],"date-time":"2016-02-08T00:00:00Z","timestamp":1454889600000}}],"reference-count":62,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011346.pub2","type":"journal-article","created":{"date-parts":[[2016,2,9]],"date-time":"2016-02-09T04:46:23Z","timestamp":1454993183000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Aflibercept for neovascular age-related macular degeneration"],"prefix":"10.1002","volume":"2016","author":[{"given":"Salman","family":"Sarwar","sequence":"first","affiliation":[{"name":"University of Nebraska Medical Center; Stanley M. Truhlsen Eye Institute; 3902 Leavenworth Street Omaha Nebraska USA 68105"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Clearfield","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health; Department of Epidemiology; 615 N. Wolfe Street Room 6014 Baltimore Maryland USA 21205"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Kamel","family":"Soliman","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center; Stanley M. Truhlsen Eye Institute; 3902 Leavenworth Street Omaha Nebraska USA 68105"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali","family":"Sadiq","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center; Stanley M. Truhlsen Eye Institute; 3902 Leavenworth Street Omaha Nebraska USA 68105"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Baldwin","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center; Stanley M. Truhlsen Eye Institute; 3902 Leavenworth Street Omaha Nebraska USA 68105"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Hanout","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center; Stanley M. Truhlsen Eye Institute; 3902 Leavenworth Street Omaha Nebraska USA 68105"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniruddha","family":"Agarwal","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center; Stanley M. Truhlsen Eye Institute; 3902 Leavenworth Street Omaha Nebraska USA 68105"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir J","family":"Sepah","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center; Stanley M. Truhlsen Eye Institute; 3902 Leavenworth Street Omaha Nebraska USA 68105"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana V","family":"Do","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center; Stanley M. Truhlsen Eye Institute; 3902 Leavenworth Street Omaha Nebraska USA 68105"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan Dong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center; Stanley M. Truhlsen Eye Institute; 3902 Leavenworth Street Omaha Nebraska USA 68105"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,2,8]]},"reference":[{"issue":"9","key":"10.1002\/14651858.CD011346.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.ophtha.2015.04.018","article-title":"Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab","volume":"122","author":"Freund","year":"2015","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD011346.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011346.pub2-BIB0003|cit3","first-page":"41","article-title":"Intravitreal aflibercept versus ranibizumab for neovascular age-related macular degeneration: 52-week subgroup analyses from the combined VIEW studies","volume":"40","author":"Mitchell","year":"2012","journal-title":"Clinical and Experimental Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD011346.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.ophtha.2015.08.014","article-title":"Scheduled versus pro re nata dosing in the VIEW trials","volume":"122","author":"Richard","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD011346.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration. Ninety-six week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD011346.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ophtha.2014.11.017","article-title":"Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration","volume":"122","author":"Schmidt-Erfurth","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD011346.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ophtha.2014.09.024","article-title":"Improvement in vision-related function with intravitreal aflibercept. Data from phase 3 studies in wet age-related macular degeneration","volume":"122","author":"Yuzawa","year":"2015","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD011346.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.ophtha.2015.04.018","article-title":"Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab","volume":"122","author":"Freund","year":"2015","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD011346.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011346.pub2-BIB0010|cit10","first-page":"41","article-title":"Intravitreal aflibercept versus ranibizumab for neovascular age-related macular degeneration: 52-week subgroup analyses from the combined VIEW studies","volume":"40","author":"Mitchell","year":"2012","journal-title":"Clinical and Experimental Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD011346.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/bjophthalmol-2014-305076","article-title":"Efficacy and safety of intravitreal aflibercept injection in wet-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study","volume":"99","author":"Ogura","year":"2015","journal-title":"British Journal of Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD011346.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.ophtha.2015.08.014","article-title":"Scheduled versus pro re nata dosing in the VIEW trials","volume":"122","author":"Richard","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD011346.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration. Ninety-six week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD011346.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ophtha.2014.11.017","article-title":"Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration","volume":"122","author":"Schmidt-Erfurth","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD011346.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ophtha.2014.09.024","article-title":"Improvement in vision-related function with intravitreal aflibercept. Data from phase 3 studies in wet age-related macular degeneration","volume":"122","author":"Yuzawa","year":"2015","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD011346.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1522.e1","DOI":"10.1016\/j.ophtha.2006.05.055","article-title":"A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration","volume":"113","author":"Nguyen","year":"2006","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD011346.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1007\/s00417-014-2641-3","article-title":"The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters","volume":"252","author":"Elshout","year":"2014","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD011346.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00417-014-2717-0","article-title":"Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration","volume":"252","author":"Yoshida","year":"2014","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD011346.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/aos.12604","article-title":"Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial","volume":"93","author":"Zehetner","year":"2015","journal-title":"Acta Ophthalmologica"},{"issue":"3","key":"10.1002\/14651858.CD011346.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1167\/iovs.14-16204","article-title":"Scleral thinning after repeated intravitreal injections of antivascular endothelial growth factor agents in the same quadrant","volume":"56","author":"Zinkernagel","year":"2015","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD011346.pub2-BIB0021|cit21","unstructured":"American Academy of Ophthalmology Retina\/Vitreous Panel Preferred Practice Pattern\u00ae Guidelines. Age-Related Macular Degeneration San Francisco, CA: American Academy of Ophthalmology; 2015. www.aao.org\/ppp"},{"issue":"9","key":"10.1002\/14651858.CD011346.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1001\/archopht.123.9.1207","article-title":"Responsiveness of the National Eye Institute Visual Function Questionnaire to progression to advanced age-related macular degeneration, vision loss, and lens opacity: AREDS report no. 14","volume":"123","author":"Age-Related Eye Disease Study Research Group","year":"2005","journal-title":"Archives of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD011346.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0039-6257(05)80092-X","article-title":"An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group","volume":"39","author":"Bird","year":"1995","journal-title":"Survey of Ophthalmology"},{"issue":"14","key":"10.1002\/14651858.CD011346.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011346.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.ophtha.2011.02.039","article-title":"Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"issue":"20","key":"10.1002\/14651858.CD011346.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011346.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2415-10-31","article-title":"Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis","volume":"10","author":"Chakravarthy","year":"2010","journal-title":"BMC Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD011346.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.ophtha.2004.07.024","article-title":"Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: quality-of-life findings: SST Report No. 14","volume":"111","author":"Childs","year":"2004","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD011346.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/archopht.121.2.211","article-title":"National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10","volume":"121","author":"Clemons","year":"2003","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD011346.pub2-BIB0030|cit30","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD011346.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ophtha.2011.10.019","article-title":"Detection of new-onset choroidal neovascularization using optical coherence tomography: the AMD DOC Study","volume":"119","author":"Do","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD011346.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ajo.2004.02.011","article-title":"Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST Report No. 4","volume":"138","author":"Dong","year":"2004","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD011346.pub2-BIB0033|cit33","unstructured":"US Food Drug Administration FDA news release (2011): FDA approves Eylea for eye disorder in older people www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm280601.htm"},{"issue":"4","key":"10.1002\/14651858.CD011346.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1684\/ecn.2009.0170","article-title":"VEGF-A: a critical regulator of blood vessel growth","volume":"20","author":"Ferrara","year":"2009","journal-title":"European Cytokine Network"},{"issue":"4","key":"10.1002\/14651858.CD011346.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/archopht.1986.01050160069013","article-title":"Earliest symptoms caused by neovascular membranes in the macula","volume":"104","author":"Fine","year":"1986","journal-title":"Archives of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD011346.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.1941.00870100042005","article-title":"Prevalence of age-related macular degeneration in the United States","volume":"122","author":"Friedman","year":"2004","journal-title":"Archives of Ophthalmology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD011346.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ophtha.2013.01.057","article-title":"Current anti-vascular endothelial growth factor dosing regimens: benefits and burden","volume":"120","author":"Haller","year":"2013","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD011346.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.ophtha.2011.03.020","article-title":"The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing","volume":"118","author":"Heier","year":"2011","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD011346.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD011346.pub2-BIB0040|cit40","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 www.cochrane-handbook.org"},{"issue":"17","key":"10.1002\/14651858.CD011346.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1002\/14651858.CD011346.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00055735-200206000-00007","article-title":"Risk factors for age-related macular degeneration: an update","volume":"13","author":"Hyman","year":"2002","journal-title":"Current Opinion in Ophthalmology"},{"issue":"9900","key":"10.1002\/14651858.CD011346.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD011346.pub2-BIB0044|cit44","first-page":"65","article-title":"The off-label use of medication: the latest on the Avastin - Lucentis debacle","volume":"32","author":"Jansen","year":"2013","journal-title":"Medicine and Law"},{"issue":"1","key":"10.1002\/14651858.CD011346.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0002-9394(99)00169-5","article-title":"Influence of age-related maculopathy on visual functioning and health-related quality of life","volume":"128","author":"Mangione","year":"1999","journal-title":"American Journal of Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD011346.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.ophtha.2004.07.022","article-title":"Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality-of-life findings: SST Report No. 12","volume":"111","author":"Miskala","year":"2004","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD011346.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1185\/03007995.2011.585394","article-title":"A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab","volume":"27","author":"Mitchell","year":"2011","journal-title":"Current Medical Research and Opinion"},{"issue":"9","key":"10.1002\/14651858.CD011346.pub2-BIB0048|cit48","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011230.pub2","article-title":"Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration","author":"Moja","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011346.pub2-BIB0049|cit49","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"14","key":"10.1002\/14651858.CD011346.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"47","key":"10.1002\/14651858.CD011346.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"18363","DOI":"10.1073\/pnas.0708865104","article-title":"VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade","volume":"104","author":"Rudge","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1002\/14651858.CD011346.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/bjophthalmol-2014-305149","article-title":"Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis","volume":"99","author":"Schmid","year":"2015","journal-title":"British Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD011346.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/ICU.0b013e3283386783","article-title":"Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review","volume":"21","author":"Schmucker","year":"2010","journal-title":"Current Opinion in Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD011346.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"e42701","DOI":"10.1371\/journal.pone.0042701","article-title":"A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus gold standard","volume":"7","author":"Schmucker","year":"2012","journal-title":"PloS One"},{"issue":"24","key":"10.1002\/14651858.CD011346.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/hmg\/ddg348","article-title":"Analysis of the ARMD1 locus: evidence that a mutation in HEMICENTIN-1 is associated with age-related macular degeneration in a large family","volume":"12","author":"Schultz","year":"2003","journal-title":"Human Molecular Genetics"},{"issue":"8","key":"10.1002\/14651858.CD011346.pub2-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005139.pub3","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","author":"Solomon","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD011346.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/bjo.2007.134874","article-title":"Predicted biological activity of intravitreal VEGF Trap","volume":"92","author":"Stewart","year":"2008","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD011346.pub2-BIB0058|cit58","first-page":"495","article-title":"Comparrative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration","volume":"7","author":"Thomas","year":"2013","journal-title":"Clinical Opthahalmology"},{"issue":"9","key":"10.1002\/14651858.CD011346.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/sj.eye.6701978","article-title":"Smoking and age-related macular degeneration: a review of association","volume":"19","author":"Thornton","year":"2005","journal-title":"Eye"},{"issue":"1","key":"10.1002\/14651858.CD011346.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ophtha.2007.03.008","article-title":"The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis","volume":"115","author":"Wong","year":"2008","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD011346.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"The Lancet Global Health"},{"issue":"10","key":"10.1002\/14651858.CD011346.pub2-BIB0062|cit62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011346","article-title":"Aflibercept for neovascular age-related macular degeneration","author":"Sarwar","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011346.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T22:57:21Z","timestamp":1715813841000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011346.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,2,8]]},"references-count":62,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011346.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,8]]}}}